Dr. Dietrich A. Stephan is the CEO, Chairman, and Founder of NeuBase Therapeutics, which is developing a new class of precision genetic medicines to address rare and common diseases at the base level. At NeuBase, he brings his deep expertise in genetic diseases, personalized medicine, and first-in-class therapeutic development to redefine medicine for millions of patients with limited treatment options. Dr. Stephan identified the molecular basis of dozens of rare and common diseases published extensively in journals and has helped launch 14 biotechnology companies to advance novel molecular diagnostics and first-in-class therapeutics to market. These companies include Navigenics, Pendulum, and Peptilogics. Dietrich remains inspired by the army of scientists and biotechnologists who battle daily for the lives of those suffering and dying needlessly from disease.
There is no arguing that the last year has been a rocky one for biotech companies, but trends suggest that the sector is ready for an upswing. The revenue model works, innovation continues to bear fruit, and the need is ever-present. The harsh winter will result in a hearty harvest.
The model of investing huge amounts of money into one drug to try to recoup it later is problematic at best and unsustainable at worst. Platform technology provides a better, more cost-effective way forward.
Break down the silos. Take control of your provider data.